/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/hem---lymphoma/,

/clinical/cckm-tools/content/beacon-protocols/hem---lymphoma/name-96862-en.cckm

201711321

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Hem - Lymphoma

CSC Hem Inpt Rituximab With Dexa-Minibeam Ver 11-17-17 (HL 2010)

CSC Hem Inpt Rituximab With Dexa-Minibeam Ver 11-17-17 (HL 2010) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Hem - Lymphoma


CSC HEM INPT RITUXIMAB WITH DEXA-MINIBEAM VER: 11-17-17 –  Properties
Cycle 1 –  11/16/2017 through 12/6/2017 (21 days), Planned
Days 1 through 6 (Inpatient), Cycle 1 –  Planned for 11/16/2017 through 11/21/2017
Treatment Plan Information
Reference Information (1)
NON-HODGKIN LYMPHOMA/HODGKIN DISEASE: Colwill R, et al. J Clin Oncol 1995;13:396-402.
Reference Information (2)
NON-HODGKIN LYMPHOMA/HODGKIN DISEASE: Atta J, et al. Leuk. Lymphoma 2007;48(2):349-56.
Reference Information (3)
NON-HODGKIN LYMPHOMA/HODGKIN DISEASE: Kirschey S, et al. Br J Haematol 2015;168(6):824-34
Treatment Plan Summary
DISEASE: Non-Hodgkin Lymphoma/Hodgkin Disease; THERAPY: rituximab 375 mg/m2 IV Day 1, dexamethasone 8 mg
by mouth three times a day Day 1 through 10, carmustine 60 mg/m2 IV Day 1, etoposide 75 mg/m2 IV Day 2 through
5, cytarabine 100 mg/m2 IV every 12 hours Day 2 through 5, melphalan 30 mg/m2 IV Day 6; CYCLE LENGTH: 21 days;
COURSE: 1 to 2 cycles, consider additional cycles if responsive and required to maintain response prior to transplant.
Note to All Staff (1)
Reactivation of hepatitis B virus (HBV) may occur and in some cases result in fulminant hepatitis, hepatic failure, or
death. Screen patients for HBV infection prior to rituximab treatment and consider prophylaxis against reactivation.
Consent
Verify Consent
Verify informed consent has been obtained.
Pre-Labs
CBC WITH DIFFERENTIAL
ONCE Starting when released, Routine
CREATININE
ONCE Starting when released, Routine
POTASSIUM
ONCE Starting when released, Routine
LD, TOTAL
ONCE Starting when released
URIC ACID
ONCE Starting when released
HEPATITIS B CORE AB, TOTAL
ONCE Starting when released
HEPATITIS B SURFACE AG
ONCE Starting when released
HEPATITIS B SURFACE AB
ONCE Starting when released
Pre-Labs (delete all that do not apply)
HEPATITIS B DNA, ULTRA QUANT, PCR
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 1 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

ONCE Starting when released
Draw if Hepatitis B Core AB is positive.
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF.
Treatment Parameters
Hold and notify authorizing prescriber for ANC less than or equal to 1,000/µL or Platelets less than or equal to 50K/µL.
Nursing Procedure, Assessment and Monitoring
Hypersensitivity Monitoring (1)
Hypersensitivity reaction to rituximab can occur and is most common with the first or second dose or if greater than 6
months since last dose. For first and second dose patient should be treated in a location to optimize emergency care.
See Emergency Meds.
Monitoring Parameters (1)
Educate patients regarding the potential of occurence for severe mucocutaneous reactions with rituximab.
Monitoring Parameters (2)
Monitor for cerebellar toxicity (incoordination, slurred speech) with neurology checks prior to each dose of cytarabine
and as needed.  For any symptoms or concerns of toxicity, hold cytarabine and contact Hematology Fellow or Staff on
call.
Vital Signs
SEE COMMENTS Starting when released Until Specified
Monitor Vital Signs every 15 minutes for the first 60 minutes and then every 30 minutes until rituximab infusion
complete. If patient experiences fever accompanied by chills or rigors, shortness of breath, chest pain, or hypotension,
stop infusion and contact MD. Once the patient returns to baseline, infusion may be restarted at half the rate during
which the reaction occurred.
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 100 mL/hr, Intravenous, CONTINUOUS Starting when released Until Discontinued
Day 1-6: Administer during chemotherapy.
Pre-Medications
acetaMINOPHEN (TYLENOL) tab 650 mg
650 mg, Oral, ONCE, 1 dose Starting when released
Administer prior to rituximab.
diphenhydramine (BENADRYL) cap 25 mg
25 mg, Oral, ONCE, 1 dose Starting when released
Administer prior to rituximab.
ondansetron (ZOFRAN) tab 16 mg
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 2 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

16 mg, Oral, 1 X DAILY, 6 doses Starting when released
Day 1-6: Administer prior to chemotherapy. May give IV if PO not tolerated.
ondansetron (ZOFRAN) 16 mg in sodium chloride 0.9 % 50 mL bag
16 mg, Intravenous, 1 X DAILY PRN, For 6 days Starting when released until S+6, nausea/vomiting
Day 1-6: Give IV if PO not tolerated.
Emergency Medications
diphenhydramine (BENADRYL) injection 50 mg
50 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction, Administer over 1 Minutes
dexamethasone (DECADRON) 10 MG/ML injection 10 mg
10 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction
famotidine (PEPCID) injection 20 mg
20 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction
albuterol 2.5 mg/3 mL neb soln
2.5 mg, Nebulization, PRN, 1 dose Starting when released, infusion reaction
Treatment Medications
dexamethasone (DECADRON) tab 8 mg
8 mg, Oral, 3 X DAILY (AT MEALTIME), 30 doses Starting when released
Day 1-10: Administer first dose prior to carmustine.
rituximab (RITUXAN) 700 mg in sodium chloride 0.9 % 500 mL bag
700 mg (rounded from 735 mg = 375 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous,
ONCE, 1 dose Starting when released
Day 1: Hypersensitivity Risk. See Emergency Medications. Administer rituximab prior to any chemotherapy. See Note on
MAR for infusion rates. If patient experiences fever accompanied by chills or rigors, shortness of breath, chest pain or
hypotension, contact MD. Once the patient returns to baseline, infusion may be restarted at half the rate during which
the reaction occurred.
carmustine (BiCNU) 117.667 mg in sodium chloride 0.9 % 250 mL non-PVC bag
117.667 mg (rounded from 117.6 mg = 60 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous,
ONCE, 1 dose Starting when released
Day 1: Administer over 120 minutes with Non-PVC tubing
etoposide (VEPESID) 147 mg in sodium chloride 0.9 % 500 mL NSS bag
147 mg (75 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, 1 X DAILY, 4 doses Starting S+1
As Scheduled
Day 2 through 5. Administer over 60 minutes. Administer with non-PVC tubing.
cytarabine PF (CYTOSAR) 196 mg in sodium chloride 0.9 % 250 mL bag
196 mg (100 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, EVERY 12 HOURS, 8 doses
Starting S+1 at 0000
Days 2 through 5
melphalan (ALKERAN) injection 59 mg
59 mg (rounded from 58.8 mg = 30 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE,
1 dose Starting S+5 at 0000, Administer over 15 Minutes
Day 6: Administer over 15 minutes. Pharmacist and RN must coordinate timing of administration to allow
administration of dose as close as possible to time of dose preparation due to poor stability and short expiration of
drug. Drug must be given within 60 minutes of reconstitution.
Treatment Medications (delete all that do not apply)
TBO-filgrastim (GRANIX) 300 MCG/0.5ML soln prefilled syringe
Subcutaneous, 1 X DAILY (PM) Starting S+7 As Scheduled
Begin on Day 8 and continue until ANC is greater than 2000//µL after nadir
Supportive Care Medications (delete all that do not apply)
acyclovir (ZOVIRAX) tab 400 mg
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 3 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

400 mg, Oral, 2 X DAILY Starting S As Scheduled
famotidine (PEPCID) tab 20 mg
20 mg, Oral, 1 X DAILY Starting when released
fluconazole (DIFLUCAN) tab 400 mg
400 mg, Oral, 1 X DAILY Starting when released
sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tab 1 tab
1 tab, Oral, 2 X DAILY SAT, SUN Include Now
Conditional Orders
ondansetron (ZOFRAN) tab 8 mg
8 mg, Oral, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
Do not exceed total of 24 mg ondansetron per 24 hours (scheduled and PRN)
ondansetron (ZOFRAN) injection 8 mg
8 mg, Intravenous, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting, If unable to
tolerate PO., Administer over 3 Minutes
Do not exceed total of 24 mg of ondansetron per 24 hours (scheduled and PRN). Administer over 3 to 5 minutes
prochlorperazine (COMPAZINE) tab 10 mg
10 mg, Oral, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea
prochlorperazine (COMPAZINE) injection 10 mg
10 mg, Intravenous, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea/vomiting, if unable to
tolerate PO
IV push slowly, max rate 5 mg/minute.
Take Home Medications (delete all that do not apply)
TBO-filgrastim (GRANIX) 300 MCG/0.5ML soln prefilled syringe
Inject 300 mcg under skin one time daily in evening. Begin Day ***. Continue until ANC is greater than *** after
nadir., 300 mcg, Disp-10 Syringe, R-5, 1 X DAILY (PM) starting S, Local Printer
RPh may substitute filgrastim at an equivalent dose and qty based on insurance coverage.
TBO-filgrastim (GRANIX) 480 MCG/0.8ML soln prefilled syringe
Inject 480 mcg under skin one time daily in evening. Begin Day ***. Continue until ANC is greater than *** after
nadir., 480 mcg, Disp-10 Syringe, R-5, 1 X DAILY (PM) starting S, Local Printer
RPh may substitute filgrastim at an equivalent dose and qty based on insurance coverage.
Follow-Up
MULTIPLE DAY FOLLOW-UP (1)
INTERIM LAB APPOINTMENTS: CBC with DIFF every Monday and Thursday starting *** and Creatinine, Potassium,
Uric Acid, and LDH twice weekly for one week starting ***
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC (DIFF if done locally), Creatinine;
NOTE: Admit to B6/6 through clinic.
Cycle 2 –  12/7/2017 through 12/27/2017 (21 days), Planned
Days 1 through 6 (Inpatient), Cycle 2 –  Planned for 12/7/2017 through 12/12/2017
Treatment Plan Information
Treatment Plan Summary
DISEASE: Non-Hodgkin Lymphoma/Hodgkin Disease; THERAPY: rituximab 375 mg/m2 IV Day 1, dexamethasone 8 mg
by mouth three times a day Day 1 through 10, carmustine 60 mg/m2 IV Day 1, etoposide 75 mg/m2 IV Day 2 through
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 4 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

5, cytarabine 100 mg/m2 IV every 12 hours Day 2 through 5, melphalan 30 mg/m2 IV Day 6; CYCLE LENGTH: 21 days;
COURSE: 1 to 2 cycles, consider additional cycles if responsive and required to maintain response prior to transplant.
Note to All Staff (1)
Reactivation of hepatitis B virus (HBV) may occur and in some cases result in fulminant hepatitis, hepatic failure, or
death. Screen patients for HBV infection prior to rituximab treatment and consider prophylaxis against reactivation.
Consent
Verify Consent
Verify informed consent has been obtained.
Pre-Labs
CBC WITH DIFFERENTIAL
ONCE Starting when released, Routine
CREATININE
ONCE Starting when released, Routine
HEPATITIS B CORE AB, TOTAL
ONCE Starting when released
HEPATITIS B SURFACE AG
ONCE Starting when released
HEPATITIS B SURFACE AB
ONCE Starting when released
Pre-Labs (delete all that do not apply)
HEPATITIS B DNA, ULTRA QUANT, PCR
ONCE Starting when released
Draw if Hepatitis B Core AB is positive.
Treatment Conditions
Verify Labs
Verify pretreatment labs have been obtained: CBC with DIFF.
Treatment Parameters
Hold and notify authorizing prescriber for ANC less than or equal to 1,000/µL or Platelets less than or equal to 50K/µL.
Nursing Procedure, Assessment and Monitoring
Hypersensitivity Monitoring (1)
Hypersensitivity reaction to rituximab can occur and is most common with the first or second dose or if greater than 6
months since last dose. For first and second dose patient should be treated in a location to optimize emergency care.
See Emergency Meds.
Monitoring Parameters (1)
Educate patients regarding the potential of occurence for severe mucocutaneous reactions with rituximab.
Monitoring Parameters (2)
Monitor for cerebellar toxicity (incoordination, slurred speech) with neurology checks prior to each dose of cytarabine
and as needed.  For any symptoms or concerns of toxicity, hold cytarabine and contact Hematology Fellow or Staff on
call.
Vital Signs
SEE COMMENTS Starting when released Until Specified
Monitor Vital Signs every 15 minutes for the first 60 minutes and then every 30 minutes until rituximab infusion
complete. If patient experiences fever accompanied by chills or rigors, shortness of breath, chest pain, or hypotension,
stop infusion and contact MD. Once the patient returns to baseline, infusion may be restarted at half the rate during
which the reaction occurred.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 5 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 100 mL/hr, Intravenous, CONTINUOUS Starting when released Until Discontinued
Day 1-6: Administer during chemotherapy.
Pre-Medications
acetaMINOPHEN (TYLENOL) tab 650 mg
650 mg, Oral, ONCE, 1 dose Starting when released
Administer prior to rituximab.
diphenhydramine (BENADRYL) cap 25 mg
25 mg, Oral, ONCE, 1 dose Starting when released
Administer prior to rituximab.
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, 1 X DAILY, 6 doses Starting when released
Day 1-6: Administer prior to chemotherapy. May give IV if PO not tolerated.
ondansetron (ZOFRAN) 16 mg in sodium chloride 0.9 % 50 mL bag
16 mg, Intravenous, 1 X DAILY PRN, For 6 days Starting when released until S+6, nausea/vomiting
Day 1-6: Give IV if PO not tolerated.
Emergency Medications
diphenhydramine (BENADRYL) injection 50 mg
50 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction, Administer over 1 Minutes
dexamethasone (DECADRON) 10 MG/ML injection 10 mg
10 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction
famotidine (PEPCID) injection 20 mg
20 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction
albuterol 2.5 mg/3 mL neb soln
2.5 mg, Nebulization, PRN, 1 dose Starting when released, infusion reaction
Treatment Medications
dexamethasone (DECADRON) tab 8 mg
8 mg, Oral, 3 X DAILY (AT MEALTIME), 30 doses Starting when released
Day 1-10: Administer first dose prior to carmustine.
rituximab (RITUXAN) 700 mg in sodium chloride 0.9 % 500 mL bag
700 mg (rounded from 735 mg = 375 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous,
ONCE, 1 dose Starting when released
Day 1: Hypersensitivity Risk. See Emergency Medications. Administer rituximab prior to any chemotherapy. See Note on
MAR for infusion rates. If patient experiences fever accompanied by chills or rigors, shortness of breath, chest pain or
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 6 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

hypotension, contact MD. Once the patient returns to baseline, infusion may be restarted at half the rate during which
the reaction occurred.
carmustine (BiCNU) 117.667 mg in sodium chloride 0.9 % 250 mL non-PVC bag
117.667 mg (rounded from 117.6 mg = 60 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous,
ONCE, 1 dose Starting when released
Day 1: Administer over 120 minutes with Non-PVC tubing
etoposide (VEPESID) 147 mg in sodium chloride 0.9 % 500 mL NSS bag
147 mg (75 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, 1 X DAILY, 4 doses Starting S+1
As Scheduled
Day 2 through 5. Administer over 60 minutes. Administer with non-PVC tubing.
cytarabine PF (CYTOSAR) 196 mg in sodium chloride 0.9 % 250 mL bag
196 mg (100 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, EVERY 12 HOURS, 8 doses
Starting S+1 at 0000
Days 2 through 5
melphalan (ALKERAN) injection 59 mg
59 mg (rounded from 58.8 mg = 30 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE,
1 dose Starting S+5 at 0000, Administer over 15 Minutes
Day 6: Administer over 15 minutes. Pharmacist and RN must coordinate timing of administration to allow
administration of dose as close as possible to time of dose preparation due to poor stability and short expiration of
drug. Drug must be given within 60 minutes of reconstitution.
Treatment Medications (delete all that do not apply)
TBO-filgrastim (GRANIX) 300 MCG/0.5ML soln prefilled syringe
Subcutaneous, 1 X DAILY (PM) Starting S+7 As Scheduled
Begin on Day 8 and continue until ANC is greater than 2000//µL after nadir
Supportive Care Medications (delete all that do not apply)
acyclovir (ZOVIRAX) tab 400 mg
400 mg, Oral, 2 X DAILY Starting S As Scheduled
famotidine (PEPCID) tab 20 mg
20 mg, Oral, 1 X DAILY Starting when released
fluconazole (DIFLUCAN) tab 400 mg
400 mg, Oral, 1 X DAILY Starting when released
sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tab 1 tab
1 tab, Oral, 2 X DAILY SAT, SUN Include Now
Conditional Orders
ondansetron (ZOFRAN) tab 8 mg
8 mg, Oral, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting
Do not exceed total of 24 mg ondansetron per 24 hours (scheduled and PRN)
ondansetron (ZOFRAN) injection 8 mg
8 mg, Intravenous, EVERY 8 HOURS PRN Starting when released Until Discontinued, nausea/vomiting, If unable to
tolerate PO., Administer over 3 Minutes
Do not exceed total of 24 mg of ondansetron per 24 hours (scheduled and PRN). Administer over 3 to 5 minutes
prochlorperazine (COMPAZINE) tab 10 mg
10 mg, Oral, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea
prochlorperazine (COMPAZINE) injection 10 mg
10 mg, Intravenous, EVERY 6 HOURS PRN Starting when released Until Discontinued, nausea/vomiting, if unable to
tolerate PO
IV push slowly, max rate 5 mg/minute.
Take Home Medications (delete all that do not apply)
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 7 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

TBO-filgrastim (GRANIX) 300 MCG/0.5ML soln prefilled syringe
Inject 300 mcg under skin one time daily in evening. Begin Day ***. Continue until ANC is greater than *** after
nadir., 300 mcg, Disp-10 Syringe, R-5, 1 X DAILY (PM) starting S, Local Printer
RPh may substitute filgrastim at an equivalent dose and qty based on insurance coverage.
TBO-filgrastim (GRANIX) 480 MCG/0.8ML soln prefilled syringe
Inject 480 mcg under skin one time daily in evening. Begin Day ***. Continue until ANC is greater than *** after
nadir., 480 mcg, Disp-10 Syringe, R-5, 1 X DAILY (PM) starting S, Local Printer
RPh may substitute filgrastim at an equivalent dose and qty based on insurance coverage.
Follow-Up
MULTIPLE DAY FOLLOW-UP (1)
INTERIM LAB APPOINTMENTS: CBC with DIFF every Monday and Thursday starting *** and Creatinine, Potassium,
Uric Acid, and LDH twice weekly for one week starting ***
DAY 22 FOLLOW-UP
(Day 1 of next cycle) RETURN TO CLINIC for appointment with provider; LABS: CBC (DIFF if done locally), Creatinine;
NOTE: Admit to B6/6 through clinic.
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/16/2017 12:00:10 PM Page 8 of 8
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org